Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial

Edy Ippolito; Numa Cellini; C Digesù; Savino Cilla; Giovanna Mantini; Mario Balducci; Alessandra Di Lallo; Francesco Deodato; Gabriella Macchia; Mariangela Massaccesi; Gian Carlo Mattiucci; Luca Tagliaferri; Angelo Piermattei; D Cuscunà; Alessio Giuseppe Morganti

doi:10.1016/j.urolonc.2010.10.005

Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial

Edy Ippolito, Numa Cellini, C Digesù, Savino Cilla, Giovanna Mantini, Mario Balducci, Alessandra Di Lallo, Francesco Deodato, Gabriella Macchia, Mariangela Massaccesi, Gian Carlo Mattiucci, Luca Tagliaferri, Angelo Piermattei, D Cuscunà, Alessio Giuseppe Morganti

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

OBJECTIVES:: To determine the recommended phase II dose of postoperative accelerated intensity modulated radiotherapy (IMRT) for prostate cancer. MATERIAL AND METHODS:: Step and shoot IMRT with simultaneous integrated boost (SIB) was delivered in 25 fractions over 5 weeks to patients with high risk resected prostate adenocarcinoma (stage pT3-4 and/or positive surgical margins). Pelvic nodes received 45 Gy at 1.8 Gy/fraction; dose escalation was performed only to the prostate bed (planned dose escalation: 56.8 Gy at 2.27 Gy/fraction, 59.7 Gy at 2.39 Gy/fraction, 61.25 Gy at 2.45 Gy/fraction, 62.5 Gy at 2.5 Gy/fraction). Dose-limiting toxicity (DLT) was any grade ≥ 3 acute toxicity (RTOG score). RESULTS:: Twenty-five patients were treated: 7 patients at the 56.75 Gy dose level, 6 patients at each subsequent dose level. Pathologic stages were: pT2c: 2; pT3a: 11; pT3b: 12; pN0: 22; pN1: 3; R0: 7; R1: 18. Median follow-up time was 19 months (range: 6-36 months). No patient experienced DLT. Grade 1-2 acute rectal and urologic toxicity was common (17 and 22 patients, respectively). CONCLUSIONS:: The recommended dose was 62.5 Gy in 2.5 Gy/fraction. Postoperative hypofractionated IMRT SIB for prostate cancer seemed to be well tolerated and could be tested in phase II studies.

Lingua originale	English
pagine (da-a)	N/A-N/A
Rivista	Urologic Oncology
DOI	https://doi.org/10.1016/j.urolonc.2010.10.005
Stato di pubblicazione	Pubblicato - 2011

Keywords

Prostate Cancer

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.urolonc.2010.10.005

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Ippolito, E., Cellini, N., Digesù, C., Cilla, S., Mantini, G., Balducci, M., Di Lallo, A., Deodato, F., Macchia, G., Massaccesi, M., Mattiucci, G. C., Tagliaferri, L., Piermattei, A., Cuscunà, D., & Morganti, A. G. (2011). Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial. Urologic Oncology, N/A-N/A. https://doi.org/10.1016/j.urolonc.2010.10.005

@article{ffaea13c77424231aa58dda2e89e4c91,

title = "Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial",

abstract = "OBJECTIVES:: To determine the recommended phase II dose of postoperative accelerated intensity modulated radiotherapy (IMRT) for prostate cancer. MATERIAL AND METHODS:: Step and shoot IMRT with simultaneous integrated boost (SIB) was delivered in 25 fractions over 5 weeks to patients with high risk resected prostate adenocarcinoma (stage pT3-4 and/or positive surgical margins). Pelvic nodes received 45 Gy at 1.8 Gy/fraction; dose escalation was performed only to the prostate bed (planned dose escalation: 56.8 Gy at 2.27 Gy/fraction, 59.7 Gy at 2.39 Gy/fraction, 61.25 Gy at 2.45 Gy/fraction, 62.5 Gy at 2.5 Gy/fraction). Dose-limiting toxicity (DLT) was any grade ≥ 3 acute toxicity (RTOG score). RESULTS:: Twenty-five patients were treated: 7 patients at the 56.75 Gy dose level, 6 patients at each subsequent dose level. Pathologic stages were: pT2c: 2; pT3a: 11; pT3b: 12; pN0: 22; pN1: 3; R0: 7; R1: 18. Median follow-up time was 19 months (range: 6-36 months). No patient experienced DLT. Grade 1-2 acute rectal and urologic toxicity was common (17 and 22 patients, respectively). CONCLUSIONS:: The recommended dose was 62.5 Gy in 2.5 Gy/fraction. Postoperative hypofractionated IMRT SIB for prostate cancer seemed to be well tolerated and could be tested in phase II studies.",

keywords = "Prostate Cancer, Prostate Cancer",

author = "Edy Ippolito and Numa Cellini and C Diges{\`u} and Savino Cilla and Giovanna Mantini and Mario Balducci and {Di Lallo}, Alessandra and Francesco Deodato and Gabriella Macchia and Mariangela Massaccesi and Mattiucci, {Gian Carlo} and Luca Tagliaferri and Angelo Piermattei and D Cuscun{\`a} and Morganti, {Alessio Giuseppe}",

year = "2011",

doi = "10.1016/j.urolonc.2010.10.005",

language = "English",

pages = "N/A--N/A",

journal = "Urologic Oncology",

issn = "1078-1439",

publisher = "Elsevier Science Incorporated / NY Journals:Madison Square Station, PO Box 882:New York, NY 10159:(212)633-3730, EMAIL: [email protected], INTERNET: http://www.elsevier.com, Fax: (212)633-3680",

}

Ippolito, E, Cellini, N, Digesù, C, Cilla, S, Mantini, G, Balducci, M, Di Lallo, A, Deodato, F, Macchia, G, Massaccesi, M, Mattiucci, GC , Tagliaferri, L, Piermattei, A, Cuscunà, D & Morganti, AG 2011, 'Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial', Urologic Oncology, pagg. N/A-N/A. https://doi.org/10.1016/j.urolonc.2010.10.005

TY - JOUR

T1 - Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial

AU - Ippolito, Edy

AU - Cellini, Numa

AU - Digesù, C

AU - Cilla, Savino

AU - Mantini, Giovanna

AU - Balducci, Mario

AU - Di Lallo, Alessandra

AU - Deodato, Francesco

AU - Macchia, Gabriella

AU - Massaccesi, Mariangela

AU - Mattiucci, Gian Carlo

AU - Tagliaferri, Luca

AU - Piermattei, Angelo

AU - Cuscunà, D

AU - Morganti, Alessio Giuseppe

PY - 2011

Y1 - 2011

N2 - OBJECTIVES:: To determine the recommended phase II dose of postoperative accelerated intensity modulated radiotherapy (IMRT) for prostate cancer. MATERIAL AND METHODS:: Step and shoot IMRT with simultaneous integrated boost (SIB) was delivered in 25 fractions over 5 weeks to patients with high risk resected prostate adenocarcinoma (stage pT3-4 and/or positive surgical margins). Pelvic nodes received 45 Gy at 1.8 Gy/fraction; dose escalation was performed only to the prostate bed (planned dose escalation: 56.8 Gy at 2.27 Gy/fraction, 59.7 Gy at 2.39 Gy/fraction, 61.25 Gy at 2.45 Gy/fraction, 62.5 Gy at 2.5 Gy/fraction). Dose-limiting toxicity (DLT) was any grade ≥ 3 acute toxicity (RTOG score). RESULTS:: Twenty-five patients were treated: 7 patients at the 56.75 Gy dose level, 6 patients at each subsequent dose level. Pathologic stages were: pT2c: 2; pT3a: 11; pT3b: 12; pN0: 22; pN1: 3; R0: 7; R1: 18. Median follow-up time was 19 months (range: 6-36 months). No patient experienced DLT. Grade 1-2 acute rectal and urologic toxicity was common (17 and 22 patients, respectively). CONCLUSIONS:: The recommended dose was 62.5 Gy in 2.5 Gy/fraction. Postoperative hypofractionated IMRT SIB for prostate cancer seemed to be well tolerated and could be tested in phase II studies.

AB - OBJECTIVES:: To determine the recommended phase II dose of postoperative accelerated intensity modulated radiotherapy (IMRT) for prostate cancer. MATERIAL AND METHODS:: Step and shoot IMRT with simultaneous integrated boost (SIB) was delivered in 25 fractions over 5 weeks to patients with high risk resected prostate adenocarcinoma (stage pT3-4 and/or positive surgical margins). Pelvic nodes received 45 Gy at 1.8 Gy/fraction; dose escalation was performed only to the prostate bed (planned dose escalation: 56.8 Gy at 2.27 Gy/fraction, 59.7 Gy at 2.39 Gy/fraction, 61.25 Gy at 2.45 Gy/fraction, 62.5 Gy at 2.5 Gy/fraction). Dose-limiting toxicity (DLT) was any grade ≥ 3 acute toxicity (RTOG score). RESULTS:: Twenty-five patients were treated: 7 patients at the 56.75 Gy dose level, 6 patients at each subsequent dose level. Pathologic stages were: pT2c: 2; pT3a: 11; pT3b: 12; pN0: 22; pN1: 3; R0: 7; R1: 18. Median follow-up time was 19 months (range: 6-36 months). No patient experienced DLT. Grade 1-2 acute rectal and urologic toxicity was common (17 and 22 patients, respectively). CONCLUSIONS:: The recommended dose was 62.5 Gy in 2.5 Gy/fraction. Postoperative hypofractionated IMRT SIB for prostate cancer seemed to be well tolerated and could be tested in phase II studies.

KW - Prostate Cancer

UR - http://hdl.handle.net/10807/14213

U2 - 10.1016/j.urolonc.2010.10.005

DO - 10.1016/j.urolonc.2010.10.005

M3 - Article

SN - 1078-1439

SP - N/A-N/A

JO - Urologic Oncology

JF - Urologic Oncology

ER -

Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo